Aprepitant (oral) and fosaprepitant (intravenous prodrug) are indicated for the prevention of nausea and vomiting. Initially, the development of aprepitant was for the prevention of chemotherapy-induced nausea and vomiting, but its use and indications have since expanded to include post-operative nausea and vomiting. Aprepitant now has FDA approval for both indications.
Aprepitant is a highly selective antagonist of the G-protein coupled neurokinin-1 receptor. Neurokinin-1 receptors are present in both the central and peripheral nervous systems. Their primary ligand is substance P, a nociceptive neurotransmitter. The areas in the brainstem thought to play critical roles in the vomiting reflex are the central pattern generator, the nucleus tractus solitarius (NTS), and area postrema (AP). Central neurokinin-1 receptors are found throughout these regions, allowing widespread binding of aprepitant in these critical regions. By acting as a competitive antagonist in these regions, aprepitant is thought to greatly attenuate the likelihood of initiation of the complex vomiting reflex. Peripherally, neurokinin-1 receptors exist throughout the gastrointestinal tract. Binding of aprepitant to these receptors may attenuate vagal afferent signals and contribute to aprepitant's antiemetic effect.
Chemotherapy-Induced Nausea and Vomiting (CINV)
Chemotherapy agents broadly divide into five emetogenic levels. Each level states the expected frequency of emesis if the patient receives no prophylactic antiemetic.
High – over 90 percent risk of emesis
Moderate – over 30 and up to 90 percent risk of emesis
Low – 10 to 30 percent risk of emesis
Minimal – under10 percent risk of emesis
The Multinational Association of Supportive Care in Cancer/European Society for Medical Oncology (MASCC/ESMO), the American Society of Clinical Oncology (ASCO), and the National Comprehensive Cancer Network (NCCN) make antiemetic therapy based guidelines based on the risk of emesis. An (NK-1) receptor antagonist is recommended in combination with a 5-HT3 receptor antagonist and a glucocorticoid (often dexamethasone) for highly emetogenic chemotherapy (HECT) and moderately emetogenic chemotherapy (MECT).
Aprepitant is available as a capsule for PO administration in 40 mg, 80 mg, and 125 mg strengths. It is also available in a prodrug preparation known as fosaprepitant for intravenous administration. Fosaprepitant comes in powder form for reconstitution in 150mg/ vial strength. A common recommendation for highly emetogenic chemotherapy-induced nausea and vomiting prevention (CINV) would include a 125 mg capsule given PO one hour before the administration of chemotherapy on day number one often combine with a 5-HT3 antagonist and dexamethasone. The 80 mg capsule is given 1 hour before chemotherapy on days two and three again, often combine with a 5HT-3 antagonist and dexamethasone. The intravenous preparation, fosaprepitant, is administered as a one-time 150 mg dose given 30 minutes prior to chemotherapy. No repeat dosing is necessary when using fosaprepitant. It bears mentioning that multiple dosing regimens exist based on the prescribed chemotherapy regimen and institutional practices. Consultation with the treating oncologist and pharmacist, as well as up to date reference literature, is recommended.
Postoperative nausea and vomiting (PONV) and Post-discharge nausea and vomiting (PDNV)
Aprepitant 40mg capsule is administered PO within three hours of induction for the prevention of anesthesia-induced postoperative nausea and vomiting. Due to its increased cost compared with other antiemetics used in anesthesia practice, its use should only be for patients who are at high risk of nausea and vomiting or in whom the act of vomiting would jeopardize surgical repair. The Apfel score is a validated and frequently used scoring system for the prediction of postoperative nausea and vomiting risk. Antiemetic regimens that include aprepitant can be prescribed based on the risk calculated risk. Fosaprepitant has not yet received an indication for postoperative nausea and vomiting though future use in NPO patients is under exploration. If used, it would likely have similar efficacy to an equipotent dose of aprepitant.
Chemotherapy-Induced Nausea and Vomiting (CINV)
Oral capsules may be used in the same manner as adult patients if the pediatric patient is greater than 12 years of age or under the age of 12 and greater than 30 kg. Aprepitant is available for oral suspension prepared by mixing the contents of one pouch of powder with 4.6ml of water. The resulting suspension yields a 25mg/ml strength for PO administration to pediatric patients or adults who cannot swallow capsules. For pediatric patients greater than six months of age up to 12 years old or 30 kg, the oral suspension is the dose form of choice. A common regimen for highly emetogenic chemotherapy is a dose of 3mg/kg PO 1 hour before chemotherapy on day one and 2mg/kg PO 1 hour before chemotherapy on day 2. Similar to adults, aprepitant often gets combined with a weight-based dose of ondansetron and dexamethasone on both days. Fosaprepitant may be substituted for the oral suspension if the patient is unable to tolerate PO administration and has intravenous (IV) access. The dosing of fosaprepitant is age-stratified and adjusted within age group depending on whether it is used as a monotherapy or combined with dexamethasone and a 5HT-3 antagonist. It is worth noting that multiple dosing regimens exist based on the prescribed chemotherapy regimen and institutional practices just as in adults. Consultation with the treating oncologist and pharmacist, as well as up to date reference literature, is recommended.
Postoperative nausea and vomiting (PONV) and post-discharge nausea and vomiting (PDNV)
Aprepitant and fosaprepitant have not received FDA approval for the indication of prophylaxis of anesthesia-induced postoperative nausea and vomiting in the pediatric population, though literature does exist demonstrating efficacy and safety.
Aprepitant and fosaprepitant are generally very well tolerated with minimal side effects. It tolerability is comparable to other low side effect antiemetic such as single doses of ondansetron. Common, less common, and rare side effects have a lower incidence when dosed at 40 mg PO once for postoperative nausea and vomiting prophylaxis when compared to a higher dose and multiple administration chemotherapy-induced nausea and vomiting prophylaxis regimens.
Common side effects (defined as greater than 10 percent incidence) headache, fatigue, anorexia, constipation, diarrhea, nausea, and hiccups (EMEND, 2013).
Less common side effects (defined as 1 to 10 percent incidence) include dizziness, insomnia, bradycardia, hypotension, pharyngolaryngeal pain, mucosal inflammation, stomatitis, dyspepsia, anemia, neutropenia, hot flash, pruritus, dehydration, and fever (EMEND, 2013).
Rare side effects (defined as less than one percent incidence) include candidiasis, staphylococcal infection, febrile neutropenia, weight gain, polydipsia, disorientation, euphoria, vivid dreams, cognitive disorder, lethargy, somnolence, conjunctivitis, cough, acid reflux, epigastric discomfort, malaise, and chills (EMEND, 2013).
Aprepitant is a dose-dependent inhibitor and inducer of the cytochrome P450 CYP34A family of enzymes. Any medication or substance metabolized by this pathway may be affected, resulting in clinically appreciable effects. Commonly cited interactions include benzodiazepines, warfarin, ketoconazole, oral hormonal contraceptives, and dexamethasone. A dose reduction in dexamethasone is recommended when coadministered with aprepitant or fosaprepitant. Patients taking oral contraceptive medications should use a backup means of contraception or abstain from sexual activity to reduce the chances of an unplanned pregnancy. A pregnancy test is necessary if the patient misses a menstrual cycle.
There are few contraindications to the use of aprepitant or fosaprepitant. Hypersensitivity, severe prior reaction, and the co-administration of pimozide or cisapride are the commonly cited ones. Relative contraindications would include medications that get metabolized via CYP3A4 metabolism and that have narrow therapeutic indices as the decreased metabolism of these medications may cause toxicity.
There are no recommendations for routine monitoring. Patients taking warfarin should have an INR check at week following single-dose aprepitant administration due to aprepitant causing increased warfarin levels via CYP34A inhibition. A pregnancy test is necessary if the patient misses a menstrual cycle.
Aprepitant has a very high therapeutic index. Case reports of toxicity due to overdose are sparse or non-existent. No specific antidote exists for aprepitant toxicity.
Chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV) result in decreased patient satisfaction, increased patient stress, and potentially increased rates of admission or delayed discharge from healthcare facilities. Well tolerated new therapies are in development that are highly effective and have few side effects. Aprepitant and its IV prodrug fosaprepitant belong to a new class of antiemetics known as neurokinin-1 inhibitors. These highly selective medications bind to multiple areas in the brainstem responsible for the initiation and coordination of the vomiting reflex. Aprepitant binds to NK-1 receptors in multiple areas of the brainstem, exerting its antiemetic effect for up to 48 hours. Aprepitant/ fosaprepitant used as monotherapy or in combination with other antiemetics can provide highly effective prophylaxis for CINV and PONV. Physicians, pharmacists, mid-level providers, and nursing staff, working as an interprofessional team, need to be aware of multiple therapies for the prevention of nausea and vomiting. Whether in the cancer center, inpatient, or operative setting, it the responsibility of all members of the healthcare team to use knowledge of antiemetic therapies to reduces rates of nausea and vomiting that can lead to adverse effects and negative patient experience. It is advisable to form interprofessional teams to develop evidence-based regimens for the prophylaxis and treatment of CINV and PONV. Including aprepitant and fosaprepitant into these regimens can lead to decreased length of hospital stay, improved patient satisfaction, and a reduction in the risk of adverse events associated with the vomiting reflex such as poor nutrition and damage to surgical repairs. Aprepitant and fosaprepitant are relatively novel and expensive therapies when compared to older antiemetics. Their use should be guided by risk stratification systems such the Apfel score, Eberhart score when prescribed for postoperative nausea and vomiting and the updated antiemetic guidelines of the Multinational Association of Supportive Care in Cancer/European Society for Medical Oncology (MASCC/ESMO), the American Society of Clinical Oncology (ASCO), and the National Comprehensive Cancer Network (NCCN). By evaluating individual patient's risks for the development of nausea and vomiting, both the cost/benefit ratio and risk/benefit ratios can be maximized. A board-certified oncology pharmacist can work closely with oncology staff to ensure proper dosing and the lack of drug interactions when choosing chemotherapy-induced antiemetic therapy. The nursing staff should understand the interactions and adverse event profile of these drugs along with the chemotherapy so that they can inform the rest of the team promptly should issues arise. These interprofessional strategies can maximize therapeutic outcomes while minimizing adverse events, enhancing patient results. [Level 5]
|||Tattersall FD,Rycroft W,Francis B,Pearce D,Merchant K,MacLeod AM,Ladduwahetty T,Keown L,Swain C,Baker R,Cascieri M,Ber E,Metzger J,MacIntyre DE,Hill RG,Hargreaves RJ, Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology. 1996; [PubMed PMID: 9121615]|
|||Di Maio M,Bria E,Banna GL,Puglisi F,Garassino MC,Lorusso D,Perrone F, Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors. Anti-cancer drugs. 2013 Feb; [PubMed PMID: 23165435]|
|||Chen S,Lu M,Liu D,Yang L,Yi C,Ma L,Zhang H,Liu Q,Frimurer TM,Wang MW,Schwartz TW,Stevens RC,Wu B,Wüthrich K,Zhao Q, Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography. Nature communications. 2019 Feb 7; [PubMed PMID: 30733446]|
|||Hornby PJ, Central neurocircuitry associated with emesis. The American journal of medicine. 2001 Dec 3; [PubMed PMID: 11749934]|
|||Miller AD,Leslie RA, The area postrema and vomiting. Frontiers in neuroendocrinology. 1994 Dec; [PubMed PMID: 7895890]|
|||Becker DE, Nausea, vomiting, and hiccups: a review of mechanisms and treatment. Anesthesia progress. 2010 Winter; [PubMed PMID: 21174569]|
|||Poli-Bigelli S,Rodrigues-Pereira J,Carides AD,Julie Ma G,Eldridge K,Hipple A,Evans JK,Horgan KJ,Lawson F, Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003 Jun 15; [PubMed PMID: 12784346]|
|||Aapro M,Carides A,Rapoport BL,Schmoll HJ,Zhang L,Warr D, Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. The oncologist. 2015 Apr; [PubMed PMID: 25795636]|
|||Chawla SP,Grunberg SM,Gralla RJ,Hesketh PJ,Rittenberg C,Elmer ME,Schmidt C,Taylor A,Carides AD,Evans JK,Horgan KJ, Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer. 2003 May 1; [PubMed PMID: 12712486]|
|||Gan TJ,Diemunsch P,Habib AS,Kovac A,Kranke P,Meyer TA,Watcha M,Chung F,Angus S,Apfel CC,Bergese SD,Candiotti KA,Chan MT,Davis PJ,Hooper VD,Lagoo-Deenadayalan S,Myles P,Nezat G,Philip BK,Tramèr MR, Consensus guidelines for the management of postoperative nausea and vomiting. Anesthesia and analgesia. 2014 Jan; [PubMed PMID: 24356162]|
|||Apfel CC,Malhotra A,Leslie JB, The role of neurokinin-1 receptor antagonists for the management of postoperative nausea and vomiting. Current opinion in anaesthesiology. 2008 Aug; [PubMed PMID: 18660647]|
|||Kang HJ,Loftus S,DiCristina C,Green S,Pong A,Zwaan CM, Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group. Pediatric blood [PubMed PMID: 29893452]|
|||Salman FT,DiCristina C,Chain A,Afzal AS, Pharmacokinetics and pharmacodynamics of aprepitant for the prevention of postoperative nausea and vomiting in pediatric subjects. Journal of pediatric surgery. 2019 Jul; [PubMed PMID: 30381138]|
|||Singh PM,Borle A,Rewari V,Makkar JK,Trikha A,Sinha AC,Goudra B, Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis. Postgraduate medical journal. 2016 Feb; [PubMed PMID: 26627976]|
|||Patel P,Leeder JS,Piquette-Miller M,Dupuis LL, Aprepitant and fosaprepitant drug interactions: a systematic review. British journal of clinical pharmacology. 2017 Oct; [PubMed PMID: 28470980]|
|||Aapro MS,Walko CM, Aprepitant: drug-drug interactions in perspective. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Dec; [PubMed PMID: 20488873]|
|||Bailard N,Rebello E, Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives. British journal of clinical pharmacology. 2018 Mar; [PubMed PMID: 29266364]|
|||Gupta A,Wu CL,Elkassabany N,Krug CE,Parker SD,Fleisher LA, Does the routine prophylactic use of antiemetics affect the incidence of postdischarge nausea and vomiting following ambulatory surgery?: A systematic review of randomized controlled trials. Anesthesiology. 2003 Aug; [PubMed PMID: 12883424]|
|||Macario A,Weinger M,Truong P,Lee M, Which clinical anesthesia outcomes are both common and important to avoid? The perspective of a panel of expert anesthesiologists. Anesthesia and analgesia. 1999 May; [PubMed PMID: 10320175]|
|||Ballatori E,Roila F, Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health and quality of life outcomes. 2003 Sep 17; [PubMed PMID: 14521717]|
|||Ritchie MK,Ellison M,Ranganathan P,Sizemore D,Vallejo MC, Aprepitant: A Novel Medicaton in the Prevention of Postoperative Nausea and Vomiting. The West Virginia medical journal. 2016 Nov-Dec; [PubMed PMID: 29368823]|